No long-term benefit of prednisolone plus azathioprine in membranous nephropathy
This article has no abstract so we have provided the first paragraph of the full text.
Patients with idiopathic membranous nephropathy are sometimes treated with a combination of the antiproliferative immunosuppressant azathioprine and the corticosteroid prednisolone; however, results of a retrospective analysis of data from the Sheffield Kidney Institute in the UK indicate that this dual regimen has no long-term clinical benefits. In membranous nephropathy patients with poor prognosis, the authors recommend that other therapies, such as cyclophosphamide, ciclosporin or chlorambucil, be used.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
